These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3122023)

  • 1. Recombinants within the tyrosine kinase region of v-abl and v-src identify a v-abl segment that confers lymphoid specificity.
    Mathey-Prevot B; Baltimore D
    Mol Cell Biol; 1988 Jan; 8(1):234-40. PubMed ID: 3122023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming properties and substrate specificities of the protein tyrosine kinase oncogenes ros and src and their recombinants.
    Jong SM; Zong CS; Dorai T; Wang LH
    J Virol; 1992 Aug; 66(8):4909-18. PubMed ID: 1321277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Most of the substrates of oncogenic viral tyrosine protein kinases can be phosphorylated by cellular tyrosine protein kinases in normal cells.
    Kamps MP; Sefton BM
    Oncogene Res; 1988 Sep; 3(2):105-15. PubMed ID: 2465525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creation of a chimeric oncogene: analysis of the biochemical and biological properties of v-erbB/src fusion polypeptide.
    Privalsky ML
    J Virol; 1987 Jun; 61(6):1938-48. PubMed ID: 2883328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological detection of proteins phosphorylated at tyrosine in cells stimulated by growth factors or transformed by retroviral-oncogene-coded tyrosine kinases.
    Di Renzo MF; Ferracini R; Naldini L; Giordano S; Comoglio PM
    Eur J Biochem; 1986 Jul; 158(2):383-91. PubMed ID: 2426107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps.
    Sadowski I; Stone JC; Pawson T
    Mol Cell Biol; 1986 Dec; 6(12):4396-408. PubMed ID: 3025655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mutation in v-src that removes a single conserved residue in the SH-2 domain of pp60v-src restricts transformation in a host-dependent manner.
    Verderame MF; Kaplan JM; Varmus HE
    J Virol; 1989 Jan; 63(1):338-48. PubMed ID: 2462061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine phosphorylations in vivo associated with v-fms transformation.
    Morrison DK; Browning PJ; White MF; Roberts TM
    Mol Cell Biol; 1988 Jan; 8(1):176-85. PubMed ID: 2447483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. bcr/abl and src but not myc and ras replace v-abl in lymphoid transformation.
    Engelman A; Rosenberg N
    Mol Cell Biol; 1990 Aug; 10(8):4365-9. PubMed ID: 2164639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properties of tripartite chimeras between Src and Lck.
    Kashishian A; MacAuley A; Cooper JA
    Oncogene; 1990 Oct; 5(10):1463-70. PubMed ID: 2250908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Src homology 2 domain substitution modulates the kinase and transforming activities of the Fes protein-tyrosine kinase.
    Rogers JA; Cheng HY; Smithgall TE
    Cell Growth Differ; 2000 Nov; 11(11):581-92. PubMed ID: 11095247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential response to retinoic acid of Syrian hamster embryo fibroblasts expressing v-src or v-Ha-ras oncogenes.
    Jetten AM; Barrett JC; Gilmer TM
    Mol Cell Biol; 1986 Oct; 6(10):3341-8. PubMed ID: 3025589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic analysis of the form and function of the viral src oncogene product.
    Wyke JA; Stoker AW
    Biochim Biophys Acta; 1987 Apr; 907(1):47-69. PubMed ID: 3105582
    [No Abstract]   [Full Text] [Related]  

  • 14. Src homology 2 domain deletion mutants of p60v-src do not phosphorylate cellular proteins of 120-150 kDa.
    Wendler PA; Boschelli F
    Oncogene; 1989 Feb; 4(2):231-6. PubMed ID: 2494631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential modulation of plasminogen activator gene expression by oncogene-encoded protein tyrosine kinases.
    Bell SM; Connolly DC; Maihle NJ; Degen JL
    Mol Cell Biol; 1993 Sep; 13(9):5888-97. PubMed ID: 7689154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential.
    Franz WM; Berger P; Wang JY
    EMBO J; 1989 Jan; 8(1):137-47. PubMed ID: 2496972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src.
    Piwnica-Worms H; Saunders KB; Roberts TM; Smith AE; Cheng SH
    Cell; 1987 Apr; 49(1):75-82. PubMed ID: 3103926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetics of src: structure and functional organization of a protein tyrosine kinase.
    Parsons JT; Weber MJ
    Curr Top Microbiol Immunol; 1989; 147():79-127. PubMed ID: 2482802
    [No Abstract]   [Full Text] [Related]  

  • 19. Src-Abl tyrosine kinase chimeras: replacement of the adenine binding pocket of c-Abl with v-Src to swap nucleotide and inhibitor specificities.
    Liu Y; Witucki LA; Shah K; Bishop AC; Shokat KM
    Biochemistry; 2000 Nov; 39(47):14400-8. PubMed ID: 11087392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rous sarcoma virus variants that encode src proteins with an altered carboxy terminus are defective for cellular transformation.
    Wilkerson VW; Bryant DL; Parsons JT
    J Virol; 1985 Aug; 55(2):314-21. PubMed ID: 2991557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.